debt_leverage_profile
Near-zero debt; cash-funded pre-revenue biotech with ~$20M cash runway; 20% rate rise has negligible P&L impact
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; no material floating-rate debt; higher rates modestly reduce NPV of future cash flows and increase equity dilution cost
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
UK-based CMO manufacturing (post-Brexit regulatory friction) and US API sourcing (nomacopan biological supply concentration)
Inferred
Agent_Inference
international_expansion_readiness
Pre-revenue; no international commercial revenue; currency devaluation exposure is negligible and limited to GBP operating costs
Inferred
Agent_Inference
geographic_footprint
Operations split US/UK; GBP functional cost base creates USD-GBP translation risk; no commercial revenue in third markets
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single-source biological (nomacopan) dependency on specialist CMO likely exceeds 30% of R&D input cost; non-substitutable short-term
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biopharmaceutical; no cloud-critical revenue operations; AWS/GCP termination would disrupt data/IT but not core drug pipeline
Inferred
Agent_Inference
business_model_type_secondary
Secondary digital operations (trial data, regulatory submissions) could migrate within 60-90 days; operational disruption, not existential risk
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; company is not a software platform; clinical and regulatory data systems have moderate vendor lock-in
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is drug licensing/milestone payments, not token or investment-contract-based
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate; clinical trial data crosses US/UK/EU jurisdictions; GDPR applies to EU trial participants; CCPA limited exposure; compliance standard for biotech
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible; single-asset niche rare disease company with no market dominance; no antitrust scrutiny expected
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
0% recurring revenue currently; 100% transactional/milestone-based; pre-revenue with potential future licensing deals
Inferred
Agent_Inference
monetization_vector
Drug licensing, milestone payments, and potential royalties on approved nomacopan indications (PNH, bullous pemphigoid)
Inferred
Agent_Inference
pricing_architecture
Orphan drug pricing model; nomacopan targets rare diseases allowing premium pricing ($300K-$700K/year range comparable to complement inhibitors)
Inferred
Agent_Inference
pricing_power_rating
High potential pricing power in rare disease/orphan drug space; limited payer pushback historically for complement pathway inhibitors
Inferred
Agent_Inference
target_gross_margin_bracket
Post-approval biopharmaceutical gross margins typically 70-85%; currently negative (R&D spend phase)
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; drug therapy requires prescription and payer approval; no meaningful churn analog in clinical-stage biotech
Inferred
Agent_Inference
headcount_cost_structure
Headcount-sublinear post-approval; manufacturing outsourced; commercial scale-up requires modest headcount relative to revenue growth
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is low post-approval; incremental revenue from additional indications leverages existing IP with limited incremental fixed cost
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC irrelevant; physician adoption and payer coverage drive uptake; key metric is formulary inclusion rate per indication
Inferred
Agent_Inference
network_effect_present
No network effects; rare disease biotech value is IP/clinical data-driven, not network-dependent
Inferred
Agent_Inference
asset_efficiency_ratio
-38.2% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
High recession resistance; rare disease patients have limited therapeutic alternatives; payer coverage insulates demand from economic cycles
Inferred
Agent_Inference
customer_segment_primary
Rare disease patients (PNH, bullous pemphigoid) via specialist hematologists/dermatologists; small addressable patient population
Inferred
Agent_Inference
customer_segment_secondary
Potential pharma licensing partners as secondary segment; large-cap pharma acquirers represent key strategic customer concentration risk
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated almost entirely to clinical R&D (Phase 2/3 trials); no legacy infrastructure reallocation; fully future-state investment profile
Inferred
Agent_Inference
sec_cik
0001541157
High
SEC-EDGAR
ticker
AKTX
High
SEC-EDGAR